newsfilter
← Latest News
GlobeNewswire·

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA newly-formed portfolio